Skip to main content
Smart Investors Daily
PG

NASDAQ · PGEN

Precigen, Inc.

Healthcare · Biotechnology

$4.30

Down-$0.24 (-5.29%)

Updated Nov 17, 2026, 2:46 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.09B
P/E ratio
-2.51
Dividend yield
0.00%
52-week range
$3.04 – $8.98
Volume
3.84M
Avg. volume
4.88M

Price performance · PGEN

PGEN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

PGEN closed at $4.30 after 21 trading sessions, down 35.44% for the selected period.

Last close
$4.30
Period change
-35.44%
Period low
$4.22
Period high
$6.94
Daily close
View OHLC price history
PGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$4.44$4.455$4.26$4.303.84M
Nov 13, 2026$4.66$4.71$4.51$4.543.78M
Nov 12, 2026$4.70$4.91$4.59$4.665.32M
Nov 11, 2026$4.59$4.805$4.50$4.724.61M
Nov 10, 2026$4.61$4.72$4.40$4.526.03M
Nov 9, 2026$4.48$4.96$4.31$4.738.82M
Nov 6, 2026$4.32$4.48$4.03$4.479.24M
Nov 5, 2026$4.71$4.74$3.92$4.2226.65M
Nov 4, 2026$5.31$5.34$4.725$5.05510.48M
Nov 3, 2026$5.335$5.38$5.06$5.259.72M
Nov 2, 2026$5.36$5.48$4.905$5.1420.62M
Oct 30, 2026$6.49$7.035$6.49$6.948.1M
Oct 29, 2026$6.20$6.985$6.06$6.647.74M
Oct 28, 2026$6.06$6.345$6.03$6.083.67M
Oct 27, 2026$6.01$6.22$5.96$6.153.79M
Oct 26, 2026$6.24$6.3099$6.01$6.042.55M
Oct 23, 2026$6.35$6.38$6.15$6.194.35M
Oct 22, 2026$6.50$6.63$6.2801$6.396.25M
Oct 21, 2026$6.79$6.92$6.57$6.605.97M
Oct 20, 2026$6.62$6.945$6.51$6.836.17M
Oct 19, 2026$6.45$6.68$6.305$6.664.14M

Latest PGEN news

The latest Smart Investors Daily articles mentioning PGEN.

PGEN research

Overview

Company profile and research snapshot.

Company profile

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
PGEN recent ratings
DateFirmRatingTarget
Nov 5, 2026CitizensMarket Outperform—
Sep 25, 2026B. Riley SecuritiesBuy—
Aug 5, 2026HC Wainwright & Co.Buy—
Aug 3, 2026HC Wainwright & Co.Buy—
May 28, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule

* Widespread adoption underway * Five-year data suggest lasting disease control and prolonged freedom from surgery * New competing product said to face substantial uncertaintyBiotech in the News: The LongviewGERMANTOWN, MD / ACCESS Newswire / November 10, 2026 / Precigen Inc. (Nasdaq:PGEN) reported sharply improved third-quarter results late last week, driven by continuing rapid uptake of its flagship therapy PAPZIMEOS®, as the company achieved positive cash flow a quarter ahead of schedule and

Yahoo · Nov 9, 2026

What Makes Precigen (PGEN) a New Buy Stock

Precigen (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo · Nov 6, 2026

Precigen (PGEN) Stock Looks Fully Priced On Current Earnings

Precigen has given holders a very bumpy ride, and the key issue now is whether the recent share price puts a fair value on the earnings power behind the story. After a run that has reshaped long term returns, the question is how comfortably the current market value lines up with what the business actually earns. Over the past 3 years the stock has delivered a very large gain of about 287.2%, which puts real weight on whether that move is backed by the underlying earnings profile. The...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.